/CHRO
CHRO Stock - Channel Therapeutics Corporation
Healthcare|BiotechnologyAMEX
$1.35+7.14%
+$0.09 (+7.14%) • Jul 1
37
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.10
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CHRO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.34 – $1.36
TARGET (TP)$1.55
STOP LOSS$1.24
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.29
52W High$54.29
52W Low$1.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $199,934 |
| Gross Profit | N/A | $-2,579,418 | $-391,730 | $-209,047 | $61,349 |
| Gross Margin | N/A | N/A | N/A | N/A | 30.7% |
| Operating Income | $-7,571,449 | $-6,862,284 | $-2,318,160 | $-839,000 | $-1,353,870 |
| Net Income | $-7,955,338 | $-7,380,793 | $-2,458,589 | $-595,387 | $-660,584 |
| Net Margin | N/A | N/A | N/A | N/A | -330.4% |
| EPS | $-1.43 | $-1.28 | $-0.43 | $-0.10 | $-0.11 |
Company Overview
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CHROBeat Rate
0%
Last 3 quarters
Avg Surprise
-26.2%
EPS vs Estimate
Beats / Misses
0/2
1 met exactly
Latest EPS
$-5.30
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
0.0%
$-0.31vs$-0.31
Q4 24
-26.1%
$-0.29vs$-0.23
Q1 25
-52.4%
$-0.32vs$-0.21
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $-5.30 | — | — |
Q3 2025 | Aug 12, 2025 | — | $-0.31 | — | — |
Q2 2025 | May 13, 2025 | — | $-0.32 | — | — |
Q1 2025 | Mar 27, 2025 | $-0.21 | $-0.32 | -52.4% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.23 | $-0.29 | -26.1% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.31 | $-0.31 | 0.0% | = MET |
Q2 2024 | May 15, 2024 | — | $-0.55 | — | — |
Q2 2024 | Apr 16, 2024 | — | $-0.69 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.25 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.17 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.17 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.13 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.10 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.06 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.05 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.04 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CHRO
What is CHRO's current stock price?
Channel Therapeutics Corporation (CHRO) is currently trading at $1.35 per share. The stock has moved +7.14% today.
What is the analyst price target for CHRO?
No analyst price targets are currently available for this stock.
What sector is Channel Therapeutics Corporation in?
Channel Therapeutics Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is CHRO's market cap?
Channel Therapeutics Corporation has a market capitalization of $0.01 billion, making it a small-cap company.
Does CHRO pay dividends?
No, Channel Therapeutics Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPGN
Apexigen, Inc.
$0.39
Mkt Cap: $0.0B
BIOR
Biora Therapeutics, Inc.
$0.22
Mkt Cap: $0.0B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
CSCI
COSCIENS Biopharma Inc.
$2.11
Mkt Cap: $0.0B
IMVIF
IMV Inc.
$0.00
Mkt Cap: $0.0B
OBSV
ObsEva S.A.
$0.10
Mkt Cap: $0.0B
OMGA
Omega Therapeutics, Inc.
$0.14
Mkt Cap: $0.0B
TNFA
TNF Pharmaceuticals, Inc.
$5.20
Mkt Cap: $0.0B
TSBX
Turnstone Biologics Corp.
$0.35
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to CHRO for comparison